CD19 CAR-T cell therapy for autoimmune diseases
Part of Bones, joints & muscles, Brain & nervous system, Heart & circulation, Immune system & allergy, Skin clinical trials.
This trial tests a new type of immune cell therapy (CAR-T cells targeting CD19) for people with autoimmune diseases that haven't improved with standard treatments. The goal is to see if it is safe and can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You need to have a relapsed or refractory autoimmune disease (like lupus, rheumatoid arthritis, or Sjögren's) that hasn't responded to standard treatments.
- Your liver, kidney, blood, and heart function must be within safe limits (tests will be done to check).
- If you are of childbearing age, you must agree to use effective birth control for at least 6 months after treatment.
- You cannot have a history of CAR-T or other gene-modified cell therapy, an active infection, or certain serious diseases like cancer or severe heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR-T cell treatment for people with certain autoimmune diseases that have not responded to standard therapies. The treatment uses your own immune cells modified to target and attack disease-causing cells.
This trial tests if a special immune cell therapy (CAR-T) can help people with certain autoimmune diseases like lupus, Sjogren's syndrome, scleroderma, myositis, vasculitis, or antiphospholipid syndrome that haven't improved with standard treatments. It is a very early phase study to check safety and effectiveness.
This trial tests a new treatment using your own immune cells (CAR T-cells) targeting a protein called CD19 to control severe autoimmune diseases like lupus, Sjogren's, scleroderma, dermatomyositis, or vasculitis. The goal is to see if it's safe and can improve symptoms when other treatments haven't worked.
This study tests a type of immunotherapy called CAR-T cells for people with certain autoimmune diseases like lupus, scleroderma, or myositis. It aims to see if this treatment can help when standard medicines haven't worked well enough.
This early-phase trial tests a new CAR-T cell therapy that targets CD19 or both CD19 and BCMA to treat several autoimmune diseases like lupus, scleroderma, and vasculitis. It aims to calm the overactive immune system with a single infusion of your own engineered cells.
This study tests a new type of immune cell therapy (CAR-T cells) designed to treat severe autoimmune diseases like rheumatoid arthritis, lupus, dermatomyositis, and scleroderma that haven't responded well to standard treatments. The therapy works by modifying your own immune cells to target and eliminate the B cells that are causing your autoimmune disease.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.